Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
about
Pathophysiology of thrombotic thrombocytopenic purpuraMultiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraVon Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraPathogenesis of thrombotic microangiopathiesClinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaProteolytic processing of von Willebrand factor by adamts13 and leukocyte proteasesPrinciples of separation: indications and therapeutic targets for plasma exchange.Atypical hemolytic-uremic syndrome: a case report and literature reviewADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpuraAcquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from JapanGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy.FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.Thrombotic thrombocytopenic purpura and its diagnosis.The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.Splenectomy for the treatment of thrombotic thrombocytopenic purpura.Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two cases.Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.Treatment of thrombotic thrombocytopenic purpura.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.Thrombotic microangiopathies: an update.Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development.Thrombotic thrombocytopenic purpura induced by metronidazole vaginal gel.Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiencyADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura-like thrombocytopenia closely related to uremia: report of two cases.A case report of thrombotic thrombocytopenic purpura and severe acute renal failure post non-myeloablative allogeneic peripheral blood stem cell transplantation treated with plasma exchange and hemodialysis.Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.Recurrent thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus.Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.The kidney in thrombotic thrombocytopenic purpura.Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpuraCorrection of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.
P2860
Q24614117-1143E5BA-C116-4474-8D2E-32EB0EF74E5FQ24620546-C3DBA9EF-0AEE-4631-9ADB-89A3673CE8D2Q24651320-D94D4CF3-EA74-46FC-B1C7-4F3D6C4940C6Q24658043-B193C8AA-6E85-4957-B85E-29111DD6F21DQ26739894-B6EFFD81-F311-4D62-B7D1-C36C4949C25DQ26827966-8EF546FB-9624-4200-A17C-FBC684896EDFQ26830899-6E57D6A2-A716-4CFE-A920-1A231B57938DQ27003863-BC33534C-D40C-46AE-A5CA-5D0277EB1D38Q28083264-454F6811-2274-4D4F-9378-A5CF53F7075AQ28731380-3594A597-3B44-4DFF-8739-449B53990C00Q30276550-4B045647-7FA5-4422-88E8-34314C189B37Q30441694-67C572F3-B238-44C5-AB9D-897268A1050FQ33327295-D89DF9AB-1C14-4560-8833-FD4C6D802019Q33364650-F8FD28A1-15C3-4D26-B26D-B3F515F38694Q33365643-451F322A-357F-44EA-8CD9-9BA22190A14EQ33366296-D6A1FCCC-D0AA-433B-8973-57F898D97F17Q33366493-C3DE7E7A-F128-4B1C-A9AF-E798006449AAQ33366935-A70E474D-FB3E-459E-B5FC-6E0F6840AD09Q33368032-A8BD8E1A-B611-40A4-A434-9447F96CAE5AQ33368709-38010B9F-2D6F-404E-813D-78B9E2C2E48BQ33369692-3F056E9A-4602-4039-9E85-E114DAB697AFQ33369765-8A80D1A7-AA54-4C70-B908-3E670762C7A5Q33370956-CD85B770-D910-468E-B783-57655F032A88Q33372115-FF22AB39-2F04-4E27-9AD0-97636564B12FQ33372991-B152C6F7-F86D-4815-B641-202732343133Q33374294-C2730D8F-C55A-4038-B8E8-91F98DA87CACQ33374370-925F64F1-4B17-4A1B-AAE1-7084035C23E5Q33374478-6C1E4318-5F4A-473A-BDC5-F45D74D4558EQ33375696-57E2034B-D02E-42CE-B3ED-CB26799CF9E7Q33376071-50B4C47E-0006-4BB6-A790-D2F99CBF8629Q33376401-1DCE4530-ABBF-4486-B8E6-72C3860125ABQ33376612-70624841-E866-4B01-B761-7592466F69B4Q33376615-6F0DFEEC-629D-470C-803D-956DD124AE76Q33376683-21612BE1-E556-4085-A22A-3B7028D1E837Q33376958-B3240B3F-6FD5-47E3-BAD2-5175107E7586Q33377500-EC3F2F6C-4D92-4C92-A9BB-EEB68A5A5C25Q33378755-3147D2D9-123D-4EC6-A102-E07D3B0C97DAQ33380771-01D25F1D-5D79-418D-8883-DD9E9FA4EC94Q33381314-1837921A-F035-4E69-8DF5-A7BADC3AEAAFQ33381813-FE848BE4-E9BE-40C2-BD74-E87CA9C07F8E
P2860
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effect of plasma exchange on p ...... otic thrombocytopenic purpura.
@ast
Effect of plasma exchange on p ...... otic thrombocytopenic purpura.
@en
type
label
Effect of plasma exchange on p ...... otic thrombocytopenic purpura.
@ast
Effect of plasma exchange on p ...... otic thrombocytopenic purpura.
@en
prefLabel
Effect of plasma exchange on p ...... otic thrombocytopenic purpura.
@ast
Effect of plasma exchange on p ...... otic thrombocytopenic purpura.
@en
P1433
P1476
Effect of plasma exchange on p ...... botic thrombocytopenic purpura
@en
P2093
Lawrence T Goodnough
Richard M Kaufman
P304
P356
10.1182/BLOOD-2003-11-4035
P407
P577
2004-02-24T00:00:00Z